Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Clinical Trial of a Cancer Vaccine Targeting VEGF and KIF20A in Advanced Biliary Tract Cancer

MUTSUNORI MURAHASHI, TOSHIHISA TSURUTA, KAZUNARI YAMADA, YASUKI HIJIKATA, HISANOBU OGATA, JUNJI KISHIMOTO, SACHIKO YOSHIMURA, TETSURO HIKICHI, YOICHI NAKANISHI and KENZABURO TANI
Anticancer Research March 2021, 41 (3) 1485-1496; DOI: https://doi.org/10.21873/anticanres.14907
MUTSUNORI MURAHASHI
1Department of Advanced Cell and Molecular Therapy, Kyushu University Hospital, Fukuoka, Japan;
2Division of Oncology, Research Center for Medical Sciences, The Jikei University School of Medicine, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOSHIHISA TSURUTA
1Department of Advanced Cell and Molecular Therapy, Kyushu University Hospital, Fukuoka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUNARI YAMADA
1Department of Advanced Cell and Molecular Therapy, Kyushu University Hospital, Fukuoka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YASUKI HIJIKATA
1Department of Advanced Cell and Molecular Therapy, Kyushu University Hospital, Fukuoka, Japan;
3Project Division of ALA Advanced Medical Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HISANOBU OGATA
1Department of Advanced Cell and Molecular Therapy, Kyushu University Hospital, Fukuoka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JUNJI KISHIMOTO
4Digital Medicine Initiative, Kyushu University, Fukuoka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SACHIKO YOSHIMURA
5OncoTherapy Science, Inc., Kanagawa, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TETSURO HIKICHI
5OncoTherapy Science, Inc., Kanagawa, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOICHI NAKANISHI
6Institute of Diseases of Chest, Kyushu University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KENZABURO TANI
1Department of Advanced Cell and Molecular Therapy, Kyushu University Hospital, Fukuoka, Japan;
3Project Division of ALA Advanced Medical Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: taniken@iqb.u-tokyo.ac.jp
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: As the prognosis of biliary tract cancer (BTC) is extremely poor and treatment options are limited, new treatment modalities are urgently needed. We designed a phase II clinical trial to investigate the immune responses and clinical benefits of OCV-C01, an HLA-A*24:02–restricted three-peptide cancer vaccine targeting VEGFR1, VEGFR2, and KIF20A. Patients and Methods: Participants were patients with advanced BTC who had unresectable tumours and were refractory to standard chemotherapy. OCV-C01 was injected weekly until the discontinuance criteria were met. Results: Six participants, including four patients positive for HLA-A*24:02, were enrolled in this study for assessment of efficacy. Four out of six patients exhibited vaccine-specific T-cell responses to one or more of three antigens. Log–rank tests revealed that vaccine-specific T cell responses contributed significantly to overall survival. Conclusion: The cancer vaccine had positive effects on survival, indicating that this approach warrants further clinical studies.

Key Words:
  • Translational research
  • cancer vaccine
  • VEGF
  • KIF20A
  • biliary tract cancer
  • Received November 6, 2020.
  • Revision received January 13, 2021.
  • Accepted January 26, 2021.
  • Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles
PreviousNext
Back to top

In this issue

Anticancer Research: 41 (3)
Anticancer Research
Vol. 41, Issue 3
March 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Clinical Trial of a Cancer Vaccine Targeting VEGF and KIF20A in Advanced Biliary Tract Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
5 + 9 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Clinical Trial of a Cancer Vaccine Targeting VEGF and KIF20A in Advanced Biliary Tract Cancer
MUTSUNORI MURAHASHI, TOSHIHISA TSURUTA, KAZUNARI YAMADA, YASUKI HIJIKATA, HISANOBU OGATA, JUNJI KISHIMOTO, SACHIKO YOSHIMURA, TETSURO HIKICHI, YOICHI NAKANISHI, KENZABURO TANI
Anticancer Research Mar 2021, 41 (3) 1485-1496; DOI: 10.21873/anticanres.14907

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Clinical Trial of a Cancer Vaccine Targeting VEGF and KIF20A in Advanced Biliary Tract Cancer
MUTSUNORI MURAHASHI, TOSHIHISA TSURUTA, KAZUNARI YAMADA, YASUKI HIJIKATA, HISANOBU OGATA, JUNJI KISHIMOTO, SACHIKO YOSHIMURA, TETSURO HIKICHI, YOICHI NAKANISHI, KENZABURO TANI
Anticancer Research Mar 2021, 41 (3) 1485-1496; DOI: 10.21873/anticanres.14907
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Does Multidisciplinary Therapy at a Sarcoma Center Improve the Prognosis of Patients With Soft Tissue Sarcoma? A Retrospective Case Study at a Single Institute
  • Clinicopathological Significance and Predictive Value of High Intratumoral Tumor Budding in Patients With Breast Carcinoma Treated With Neoadjuvant Chemotherapy
  • Successful Prevention of Tumour Lysis Syndrome in HER2-positive Breast Cancer: Case Report and Literature Review
Show more Clinical Studies

Similar Articles

Keywords

  • Translational research
  • cancer vaccine
  • VEGF
  • KIF20A
  • biliary tract cancer
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire